Marcos Parrilla Rios, MD
Internal Medicine · San Lorenzo, PRNPI 1336125301
Payments from drug & device makers
Across 84 payments — averaging $24.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$877
- Takeda Pharmaceuticals U.S.A., Inc.$479
- Boehringer Ingelheim$201
- Sanofi-aventis U.S. LLC$161
- Biocryst US Sales Co., LLC$133
- GSK$53
- plus $196 from 8 others
What the payments were for
- Food & beverage$2,08699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $877 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $479 |
| Boehringer Ingelheim | 10 | $201 |
| Sanofi-aventis U.S. LLC | 8 | $161 |
| Biocryst US Sales Co., LLC | 6 | $133 |
| GSK | 4 | $53 |
| Johnson & Johnson | 2 | $50 |
| Shire North American Group Inc | 2 | $32 |
| Pfizer Pharmaceuticals LLC | 1 | $25 |
| PBG Puerto Rico LLC | 2 | $25 |
| AbbVie | 1 | $20 |
| Merck | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,100 in reported general payments places this provider in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 323 | $337,780 |
| JanuviaSitagliptin Phosphate | 220 | $251,107 |
| EliquisApixaban | 136 | $154,658 |
| FarxigaDapagliflozin Propanediol | 114 | $152,306 |
| SynthroidLevothyroxine Sodium | 1,092 | $118,369 |
| TecfideraDimethyl Fumarate | 12 | $111,072 |
| XareltoRivaroxaban | 112 | $106,935 |
| JardianceEmpagliflozin | 82 | $105,677 |
| TrulicityDulaglutide | 95 | $96,850 |
| IcatibantIcatibant Acetate | 17 | $86,166 |
| JentaduetoLinagliptin/Metformin Hcl | 107 | $71,163 |
| OzempicSemaglutide | 68 | $68,557 |
| Xigduo XrDapaglifloz Propaned/Metformin | 50 | $58,193 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $39,223 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $31,199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Januvia | $18 | $588,886543 claims |
| Boehringer IngelheimJardiance, Jentadueto, Trijardy Xr, Synjardy Xr | $201 | $213,547234 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $877 | $199,502175 claims |
| AbbVieSynthroid, Linzess, Lumigan | $20 | $137,5211,132 claims |
| Johnson & JohnsonXarelto | $50 | $106,935112 claims |
| Novo NordiskOzempic | $15 | $68,55768 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $53 | $57,96880 claims |
| Sanofi-aventis U.S. LLCLantus | $161 | $25,446155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in San Lorenzo
- Julio JimenezSan Lorenzo$99K
- Elizabeth BarrancoPonce$8M
- Grisell Ortiz LasantaSan Juan$5.9M
- Ruben Santiago-LugoGuaynabo$1.3M
- Nelson VallejoLas Piedras$621K
- Ricardo FernandezSan Juan$480K
- Ronald Collazo PaganManati$206K
- Evelyn Matta FontanetRio Grande$200K
- Angel VinuelaDorado$182K
- Lumen Vera ColonAibonito$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.